Asahi shares mark weekly slide after cyberattack halts production
TAINAN CITY, Taiwan - Advanced Biomed Inc. (NASDAQ:ADVB), a $12.2 million market cap biotech company currently trading at $0.56 per share, announced Friday the launch of its A+PerfusC system, a compact perfusion-based 3D cell culture incubator designed to replicate human physiological conditions in laboratory settings. According to InvestingPro analysis, the company appears overvalued at current levels.
The platform integrates automated perfusion with environmental control in a format that can be mounted directly onto microscopes for real-time observation. According to the company, the system supports up to 12 days of continuous, hands-free culture and can accommodate up to 4,800 tumor spheroids per plate.
Advanced Biomed stated that the system has completed internal testing and validation with finalized design, and is now advancing to mass-production development. Commercialization will follow once production development and quality control standards are established. While the company maintains a healthy current ratio of 1.88 and holds more cash than debt, InvestingPro data reveals rapid cash burn and negative EBITDA of -$2.21 million in the last twelve months.
Dr. Yi Lu, CEO of Advanced Biomed, said the system "evenly delivers nutrients and clears waste, reducing cellular stress, boosting long-term viability, and more accurately mimicking human tissue complexity."
The company indicated potential applications for the technology include personalized oncology research, in-vitro drug screening, regenerative medicine, organoid studies, and stem cell research.
According to data cited in the company’s press release, the global 3D cell culture market was valued at $2.32 billion in 2025 and is projected to reach $4.71 billion by 2030, representing a compound annual growth rate of approximately 15.6%.
Advanced Biomed is a Nevada-incorporated holding company operating through subsidiaries in Taiwan, Hong Kong, and Mainland China. The company specializes in biomedical technologies for cancer detection and precision medicine.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.